InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced that the Committee for Medicinal Products for Human ...
A new study has developed an innovative approach to combat antibiotic-resistant bacteria by tagging them with a chimeric agent that activates the immune system towards them.